Cooperative Agreement 72061221CA00012

The Tennessee Department of Health (TDH) received a $754,647 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Health Department Based (CFDA 93.940) program. The award will support TDH's Tennessee Tuberculosis (TB) Elimination Program (TTBEP) to provide oversight, clinical consultations, education, and training resources to regional TB programs across Tennessee. The program aims to eliminate TB in Tennessee through...

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $1,040,476 Cooperative Agreement to the Louisiana Department of Health (LDH), titled "Elimination of Tuberculosis Disease in Louisiana" under the HIV Prevention Activities Health Department Based program (CFDA 93.940). The award will support LDH's statewide Tuberculosis Control Program, which provides direction and support to 9 regional TB control programs serving Louisiana's 4.59 million residents. Key services to...

This $960,090 Cooperative Agreement award, funded by the National Center for HIV/AIDS and titled "HIV Prevention Activities Health Department Based" (CFDA 93.940), supports the Arkansas Department of Health (ADH) in implementing comprehensive HIV prevention and surveillance strategies across the state. The key products and services to be delivered under this 5-year award (2025-2029) include: (1) rapid diagnosis and treatment of tuberculosis (TB) disease, (2) enhanced detection and...

This federal Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under CFDA 93.940 - HIV Prevention Activities Health Department Based provides $288,944 in funding to the Idaho Department of Health & Welfare's Financial Services Division. The purpose is to support the Idaho Tuberculosis (TB) Elimination and Laboratory Program's efforts to identify and ensure adequate treatment for all individuals with active TB in the state, coordinate TB case response,...

This Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Health Department Based program (CFDA 93.940) provides $982,536 to the Ohio Department of Health (ODH) to conduct statewide tuberculosis (TB) surveillance, provide technical assistance to local TB control units, offer financial assistance for TB care, manage active TB cases, support contact investigations, ensure continuity of care, investigate TB cases and outbreaks,...

The Philadelphia Department of Public Health's Tuberculosis Control Program (TBC) received a $411,971 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under CFDA 93.116 - Project Grants and Cooperative Agreements for Tuberculosis Control Programs. This 5-year award, effective January 1, 2025 through December 31, 2029, supports TBC's efforts to eliminate tuberculosis in Philadelphia through three priority strategies: 1) identifying and treating active TB...

The Georgia Department of Public Health (GDPH) was awarded a $217,191 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Health Department Based (CFDA 93.940) program. The award, which runs from January 1, 2025 to December 31, 2029, supports GDPH's comprehensive efforts to prevent, diagnose, and manage tuberculosis (TB) across Georgia's 159 counties. Key services provided under this Cooperative Agreement include: Medical...

The Defense Health Agency awarded a $215,429 Project Grant to The Global Alliance For TB Drug Development Inc. (TB Alliance) to investigate a host-directed proteolysis-targeting chimera (PROTAC) approach for targeting intracellular Mycobacterium tuberculosis. This two-year grant, running from July 2024 to July 2026, supports TB Alliance's research and development efforts to accelerate the development of new tuberculosis (TB) drugs and treatment regimens. The funding falls under the Military...

This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Salus Discovery LLC for the development of a "FLOW DIRECT: NEXT GENERATION URINE LFA FOR TB DIAGNOSIS IN POINT-OF-CARE SETTINGS". This grant, awarded on July 10, 2024, will support Salus Discovery's research and development of an affordable, high-quality urine-based lateral flow assay (LFA) for the point-of-care...